A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma - NCT01123785-(Clinical Trial 634001)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
New York |
|
State:
|
|
NY |
| Zip Code: |
|
|
| Conditions: |
|
Glaucoma - Ocular Hypertension |
| Purpose: |
|
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give
INO-8875 eye drops to adults with glaucoma or ocular hypertension.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
(POAG).
2. Aged 18 to 75 years.
3. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.
Exclusion Criteria:
1. No significant visual field loss or any new field loss within the past year.
2. Cup-to-disc ratio ≥0.8
3. Central corneal thickness <500 µm or >600 µm
4. History of adult asthma or chronic obstructive pulmonary disease
5. A recent (acute) or chronic medical condition that might obfuscate the Subject's
study data |
|
|
|
| Study is available at: |
|
New York Eye and Ear Infirmary
New York, NY
United States
Primary Contact:
Paul A Sidoti, MD
Email: psidoti@nyee.edu
Phone: 212-979-4251
Secondary Contact:
Tiffany Crowell
Email: tcrowell@inotekcorp.com
Phone: 781-676-2100 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|